Publication | Open Access

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

OncologyRisk-benefit AnalysisMedicineMetronomic TherapyPemetrexed ComparedBronchial NeoplasmPharmacotherapyCancer TreatmentPharmacologyLung Cancer